MORE FROM THE COMPANY –
A NEWSLETTER FROM COMBIGENE
Lund, August 31 2017

FDA approves a gene therapy product from Novartis for the treatment of acute lymphoblastic leukemia.

This is the first ever approval of a gene therapy product in the US and hence an important milestone for gene therapy as such.

30 August 2017 is a historical day for gene therapy! FDA has just approved the first gene therapy for the US market. By approving Kymria from the pharmaceutical company Novartis for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL), they have demonstrated their confidence in the safety and efficacy of a gene therapy product.

This is most likely the first in a row of approved gene therapies we could expect over the nearest coming years – both in the US and Europe.

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. www.combigene.com

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
Email: jan.nilsson@combigene.com

MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com